LifeMD Dividendos y recompras
Dividendo controles de criterios 0/6
LifeMD no tiene historial de pago de dividendo.
Información clave
n/a
Rentabilidad por dividendo
-3.9%
Rendimiento de la recompra
| Rendimiento total para el accionista | -3.9% |
| Rendimiento futuro de los dividendos | n/a |
| Crecimiento de los dividendos | n/a |
| Próxima fecha de pago de dividendos | n/a |
| Fecha ex dividendo | n/a |
| Dividendo por acción | n/a |
| Ratio de pago | n/a |
Últimas actualizaciones de dividendos y recompras
No hay actualizaciones
Recent updates
Seeking Alpha • Jun 09
LifeMD: A Growing Healthcare Tech Stock, As Q1 Results Confirm Patient Demand
Summary LifeMD offers a compelling growth opportunity, driven by digital healthcare tailwinds and record net subscriber additions in Q1. LFMD trades at a significant valuation discount, with fwd EV/Sales of 0.94x and a Wall St. price target implying 102% upside. Despite strong revenue growth, LFMD faces near-term earnings pressure from elevated marketing spend and negative operating income. LFMD's integrated pharmacy network and cash-rich balance sheet enhance its competitive positioning, but weak ROE and profitability remain key risks. The company has a cash runway of about 8.2 years under current scenario, where debt payments are a major cash impact, despite operating cashflow being positive. Read the full article on Seeking Alpha
Actualización de narrativa • Jun 04
LFMD: Oral GLP-1 Virtual Care And Retention Will Shape 2026 Outlook
Analysts have raised their average price target for LifeMD to $9.88, reflecting updated views on lower perceived risk, slightly higher expected revenue growth, and a marginally lower projected profit margin, supported by recent upgrades citing stronger 2026 outlooks, Q4 beats, and patient growth potential tied to the oral GLP-1 portfolio. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher price targets, in the US$8 to US$10 range, as reflecting greater confidence in LifeMD's ability to execute on its growth plan and support a higher valuation.
Actualización de narrativa • May 19
LFMD: Oral GLP 1 Portfolio Will Anchor Future Telehealth Reacceleration
Narrative Update on LifeMD LifeMD's updated analyst price targets, which now cluster around $8 to $10, reflect analysts' focus on improved 2026 outlooks, higher projected revenue growth and margins, and a lower assumed future P/E, supported by recent research citing Q4 outperformance, user retention metrics, and the potential impact of the oral GLP-1 portfolio. Analyst Commentary Recent research shows a clear shift toward a more constructive stance on LifeMD, with bullish analysts highlighting price target increases, an upgrade to a more positive rating, and confidence in execution on growth initiatives into 2026.Actualización de narrativa • May 01
LFMD: GLP-1 Virtual Care And Retention Trends Will Drive 2026 Outlook
Analysts have nudged their average price target for LifeMD slightly higher to about $9.88, citing stronger 2026 outlooks, recent Q4 beats, and growing conviction in the company's GLP-1 driven virtual care expansion and user retention trends. Analyst Commentary Recent Street research has centered on LifeMD's updated 2026 outlook, its GLP-1 focused virtual care offering, and the impact of Q4 results on the valuation debate.Actualización de narrativa • Apr 17
LFMD: GLP-1 Weight Management And Retention Trends Will Shape 2026 Outlook
Analysts maintained their average price target for LifeMD at $9.88 per share, unchanged from the previous level, as recent research points to better supported long term forecasts tied to GLP-1 driven growth expectations, updated 2026 outlooks, and stronger user retention metrics. Analyst Commentary Recent research on LifeMD centers on how well the company can execute on its GLP-1 focused growth plans, translate user retention into sustained revenue, and deliver on its 2026 outlook while keeping valuation in line with execution risk.Actualización de narrativa • Apr 03
LFMD: GLP 1 Virtual Care Expansion Will Drive Telehealth Reacceleration
Analysts have trimmed the fair value estimate for LifeMD slightly to $14.17 from $14.22, as updated assumptions around higher expected revenue growth, improved profit margins, and a lower future P/E multiple are weighed against recent price target increases tied to stronger 2026 outlooks and GLP-1 driven virtual care expansion. Analyst Commentary Recent Street research has turned more constructive on LifeMD, with several bullish analysts revisiting their models and price targets following the latest quarterly update and 2026 outlook.Actualización de narrativa • Mar 20
LFMD: GLP-1 Focused Virtual Care Expansion Will Drive Future Weight Management Upside
The analyst price target for LifeMD has been raised from $9.25 to $9.88. Analysts attribute this to updated expectations for revenue growth, higher profit margins, and a lower assumed future P/E multiple, supported by recent research highlighting a stronger 2026 outlook, Q4 beats, and GLP-1 driven virtual care expansion.Actualización de narrativa • Mar 05
LFMD: Expanded GLP-1 Telehealth Access Will Support Future Weight Management Upside
The latest analyst price target for LifeMD now stands at $9.25, with analysts linking this valuation to updated assumptions around discount rates, profit margins, and future P/E levels. What's in the News LifeMD is now offering Novo Nordisk's Wegovy pill, described as the first and only FDA approved oral GLP-1 therapy for chronic weight management and cardiovascular health, through its telehealth platform (Key Developments).Actualización de narrativa • Feb 18
LFMD: Expanded GLP-1 Telehealth Offering Will Support Future Weight Management Upside
Analysts have modestly adjusted their price target for LifeMD to $9.25, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E expectations, while keeping their overall fair value view steady. What's in the News LifeMD is now offering Novo Nordisk's Wegovy pill, described as the first and only FDA approved oral GLP-1 therapy for chronic weight management and cardiovascular health, through its telehealth platform, expanding its branded obesity treatment options (Key Developments).Artículo de análisis • Feb 12
Why Investors Shouldn't Be Surprised By LifeMD, Inc.'s (NASDAQ:LFMD) 31% Share Price Plunge
To the annoyance of some shareholders, LifeMD, Inc. ( NASDAQ:LFMD ) shares are down a considerable 31% in the last...Actualización de narrativa • Feb 04
LFMD: Weight Management Headwinds Will Set Up Telehealth Reacceleration
Analysts have trimmed their implied fair value on LifeMD from about US$18.00 to roughly US$14.22 per share after cutting price targets to US$6 to US$10. They cited a higher discount rate, softer revenue and margin assumptions, and a much higher future P/E multiple tied to increased uncertainty following recent Q3 misses and competitive pressure in weight management.Actualización de narrativa • Jan 21
LFMD: Pure Play Telehealth Platform Will Benefit From Easing Weight Management Headwinds
Analysts have reduced their LifeMD price targets by about US$4 to US$8 per share overall, citing Q3 revenue and EBITDA misses, competitive pressure in virtual weight management, and updated guidance for the standalone telehealth and pharmacy business. Analyst Commentary Analysts are largely aligned on the key pressure points for LifeMD, but they differ in how they think those issues affect the company’s long term opportunity and valuation.Actualización de narrativa • Jan 07
LFMD: Telehealth Platform And Weight Management Headwinds Will Set Up Future Margin Expansion
Narrative Update on LifeMD Analysts have reset LifeMD's blended price target lower to around US$9, reflecting reduced targets ranging from US$6 to US$10 after Q3 top and bottom line misses and increased competitive pressure in weight management, while still recognizing the company as a focused telehealth and pharmacy platform with updated 2025 revenue guidance. Analyst Commentary Recent research updates on LifeMD reflect a mixed view, with analysts cutting price targets after Q3 revenue and EBITDA misses and increased competitive pressure in weight management, while still highlighting areas of execution progress and a more focused business model.Actualización de narrativa • Dec 17
LFMD: Telehealth Focus And Weight Management Reset Will Drive Future Margin Expansion
Analysts have trimmed LifeMD's average price target by several dollars per share, citing Q3 revenue and EBITDA misses, increased competitive pressure in weight management, and revised revenue guidance that temper near term expectations despite a still constructive long term outlook. Analyst Commentary Bullish analysts acknowledge the near term disappointment but stress that the core telehealth and pharmacy platform remains intact, with structural drivers that can support renewed growth once competitive and reimbursement dynamics in weight management stabilize.Actualización de narrativa • Dec 03
LFMD: Weight Management Headwinds Will Set Up Margin Expansion And Rebound Potential
Analysts have trimmed their consolidated price target for LifeMD to approximately $9.25 from about $10.63, reflecting reduced revenue growth expectations amid near term competitive pressures in weight management and updated 2025 guidance, partly offset by improved profit margin assumptions and a lower valuation multiple. Analyst Commentary Analysts are broadly recalibrating their LifeMD models in light of softer than expected Q3 results and updated 2025 guidance, with price targets now clustering in the mid single to low double digit range.Actualización de narrativa • Nov 19
LFMD: Competitive Pressures Will Drive Market Share Shifts After 2025 Resets
LifeMD’s analyst price target has been reduced from $12.88 to $10.63. This change reflects updated guidance and competitive headwinds that analysts link to recent financial underperformance and increased pressure in the company’s weight management business.Actualización de narrativa • Aug 07
Expanding Care Domains And Telemedicine Will Unlock New Markets
Analysts have lowered their price target for LifeMD to $13.25, reflecting ongoing regulatory and partnership risks in the GLP-1 market that offset strong platform growth and market share gains. Analyst Commentary Bullish analysts are optimistic due to LifeMD’s successful scaling of its national, tech-enabled virtual care platform, which covers multiple high-demand healthcare verticals including primary care, weight management, and behavioral health.Artículo de análisis • Aug 07
Positive Sentiment Still Eludes LifeMD, Inc. (NASDAQ:LFMD) Following 46% Share Price Slump
NasdaqGM:LFMD 1 Year Share Price vs Fair Value Explore LifeMD's Fair Values from the Community and select yours LifeMD...Artículo de análisis • Jun 21
LifeMD, Inc. (NASDAQ:LFMD) Soars 37% But It's A Story Of Risk Vs Reward
Despite an already strong run, LifeMD, Inc. ( NASDAQ:LFMD ) shares have been powering on, with a gain of 37% in the...Artículo de análisis • May 09
LifeMD, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
It's been a good week for LifeMD, Inc. ( NASDAQ:LFMD ) shareholders, because the company has just released its latest...Artículo de análisis • May 07
LifeMD, Inc.'s (NASDAQ:LFMD) Shares Leap 50% Yet They're Still Not Telling The Full Story
LifeMD, Inc. ( NASDAQ:LFMD ) shareholders would be excited to see that the share price has had a great month, posting a...
Nueva narrativa • Apr 23
New HRT, GLP-1 And Medicare Programs Will Elevate Care
Expansion in Medicare programs and integration with Gifthealth are set to enhance LifeMD's market reach and boost revenue through improved patient retention.Nueva narrativa • Apr 21
LifeMD is a diamond in the making
Telehealth is the future of healthcare in america and around the world. Most people don’t want to wait hours in the hospital or even weeks for an appointment. Telehealth offers those services the sameArtículo de análisis • Mar 31
A Look At The Intrinsic Value Of LifeMD, Inc. (NASDAQ:LFMD)
Key Insights The projected fair value for LifeMD is US$5.85 based on 2 Stage Free Cash Flow to Equity Current share...Artículo de análisis • Mar 08
It's Down 27% But LifeMD, Inc. (NASDAQ:LFMD) Could Be Riskier Than It Looks
LifeMD, Inc. ( NASDAQ:LFMD ) shares have had a horrible month, losing 27% after a relatively good period beforehand...Seeking Alpha • Feb 01
LifeMD: Dilution Ramps Up As Revenue Moves Higher
Summary LifeMD is trading at a low multiple to sales of 1.08x even as the telehealth company generates material revenue growth. The preferreds are trading a tighter discount to their $25 per share liquidation value. They now offer a roughly 10% yield on cost. Dilution is material and increased by 22% over its year-ago comp during the fiscal 2024 third quarter. Read the full article on Seeking AlphaArtículo de análisis • Dec 06
LifeMD, Inc.'s (NASDAQ:LFMD) Intrinsic Value Is Potentially 82% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, LifeMD fair value estimate is US$9.93 LifeMD is estimated to...Seeking Alpha • Dec 04
LifeMD: A Story I Want A Small Piece Of
Summary The stock of LifeMD, Inc. has started to rebound after a steep decline since May after a solid third quarter in early November. The company has also delivered positive free cash flow for four consecutive quarters, and its telehealth offerings are seeing impressive sales growth. An analysis around LifeMD follows in the paragraphs below. Read the full article on Seeking AlphaArtículo de análisis • Nov 09
LifeMD, Inc.'s (NASDAQ:LFMD) Shares Leap 31% Yet They're Still Not Telling The Full Story
LifeMD, Inc. ( NASDAQ:LFMD ) shareholders would be excited to see that the share price has had a great month, posting a...Seeking Alpha • Sep 23
LifeMD: Are The Commons Too Cheap?
Summary LifeMD has dropped 41% year-to-date even as its telehealth segment realized a fiscal 2024 second-quarter growth rate of 67%. The company's telehealth gross profit margins were up 630 basis points year-over-year during the second quarter. The market is now pricing LFMD at around 0.83x its fiscal 2025 revenue. Read the full article on Seeking AlphaSeeking Alpha • Sep 10
LifeMD: Selling WorkSimpli Could Be A Catalyst
Summary LifeMD's Q2 2024 earnings were mixed, with management failing to monetize the non-core WorkSimpli asset, leading me to assign it no value. Despite management's over-promising, LifeMD's telehealth and GLP1 offerings show significant potential, with the stock priced at 14x forward EBITDA. I have revised my price target from $20 to $15 per share by summer 2025, due to management's credibility issues and uncertainties in GLP1 prospects. LifeMD remains a compelling investment with strong fundamentals and a solid balance sheet, but it's a high-risk, high-return opportunity. Read the full article on Seeking AlphaArtículo de análisis • Aug 16
It's Down 27% But LifeMD, Inc. (NASDAQ:LFMD) Could Be Riskier Than It Looks
To the annoyance of some shareholders, LifeMD, Inc. ( NASDAQ:LFMD ) shares are down a considerable 27% in the last...Seeking Alpha • Jul 31
LifeMD: High Growth GLP-1 Telehealth Play At A Discount
Summary LifeMD is positioned as a high-growth telehealth play with a focus on GLP-1 weight management treatments. The company is guiding for 35% revenue growth in 2024. Its core telehealth business is expected to grow at least 43%. Non-core software subsidiary WorkSimpli may be spun off in the next 6 to 12 months, while the company is on track for GAAP profitability next year. Read the full article on Seeking AlphaSeeking Alpha • Jun 11
LifeMD: Pairing GLP-1 Agonists With Virtual Healthcare
Summary Identifying investment opportunities in the healthcare sector involves research on trends and next-gen tech. LifeMD offers telehealth services and weight management programs, positioned for growth in the underserved obesity market. Risks include regulatory changes, competition, cash position, and the potential need for additional funding. I present my plan for establishing a position in the near-term. Read the full article on Seeking AlphaSeeking Alpha • May 22
LifeMD: Moving Towards Profitability
Summary LifeMD, Inc. shares have been volatile over the past year, pulling back 50% from recent highs, but still having tripled in the past 12 months. GLP-1 drugs like Zepbound and Wegovy have helped turbocharge growth in LifeMD's weight management business. The company is delivering impressive and consistent sales growth and is projected to be profitable by FY2025. An updated analysis around LifeMD is presented in the paragraphs below. Read the full article on Seeking AlphaArtículo de análisis • Apr 25
Is LifeMD (NASDAQ:LFMD) Using Debt Sensibly?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Artículo de análisis • Mar 30
Even With A 29% Surge, Cautious Investors Are Not Rewarding LifeMD, Inc.'s (NASDAQ:LFMD) Performance Completely
The LifeMD, Inc. ( NASDAQ:LFMD ) share price has done very well over the last month, posting an excellent gain of 29...Seeking Alpha • Mar 13
LifeMD: Results And Guidance Point To Continued Strength In Weight Management Program
Summary LifeMD reported impressive revenue growth, with a 60% increase to $44.9 million, driven by a 90% increase in telehealth revenues. Weight management subscribers more than doubled sequentially, resulting greater than 100% revenue growth quarter over quarter from this segment. Management raised its 2024 revenue forecast to at least $200 million, indicating strong growth potential and the likelihood of analyst upward revisions. Read the full article on Seeking AlphaSeeking Alpha • Jan 22
LifeMD's 2024: Striking A Balance Between Rapid Expansion And Sustainability
Summary LifeMD, Inc.'s newly issued 2024 guidance indicates an impressive 38% CAGR, positioning it as an attractive investment opportunity. With a valuation priced at less than 11x forward EBITDA, LifeMD stock is considered advantageous, although investor skepticism persists regarding the sustainability of such growth rates in a competitive market. Despite concerns about the program's long-term sustainability, I believe the stock offers a favorable risk-reward scenario. Read the full article on Seeking AlphaSeeking Alpha • Jan 11
LifeMD: A GLP-1 Play With A Kicker
Summary LifeMD expects a 38% increase in revenues for 2024, driven by its new telehealth operation for GLP-1 obesity drugs. Despite this, the stock is down significantly due to concerns over Eli Lilly direct marketing its GLP-1 obesity drugs. These fears are overblown. LifeMD's other operations are growing quickly and it is close to achieving breakeven earnings. The WorkSimpli SaaS segment is probably worth the full market cap by itself. Read the full article on Seeking AlphaArtículo de análisis • Jan 05
Is LifeMD, Inc. (NASDAQ:LFMD) Potentially Undervalued?
LifeMD, Inc. ( NASDAQ:LFMD ), might not be a large cap stock, but it received a lot of attention from a substantial...Artículo de análisis • Jan 05
Take Care Before Jumping Onto LifeMD, Inc. (NASDAQ:LFMD) Even Though It's 34% Cheaper
LifeMD, Inc. ( NASDAQ:LFMD ) shareholders won't be pleased to see that the share price has had a very rough month...Artículo de análisis • Dec 03
Does This Valuation Of LifeMD, Inc. (NASDAQ:LFMD) Imply Investors Are Overpaying?
Key Insights Using the 2 Stage Free Cash Flow to Equity, LifeMD fair value estimate is US$6.04 LifeMD's US$7.76 share...Estabilidad y crecimiento de los pagos
Obteniendo datos sobre dividendos
Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de LFMD han sido estables en el pasado.
Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de LFMD han aumentado.
Rentabilidad por dividendo vs. Mercado
| Rentabilidad por dividendo de LifeMD vs. Mercado |
|---|
| Segmento | Rentabilidad por dividendo |
|---|---|
| Empresa (LFMD) | n/a |
| Suelo de mercado 25% (US) | 1.4% |
| Techo de mercado 25% (US) | 4.2% |
| Media de la industria (Healthcare Services) | 1.2% |
| Analista de previsiones (LFMD) (hasta 3 años) | n/a |
Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de LFMD en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.
Alto dividendo: No es posible evaluar la rentabilidad por dividendo de LFMD en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.
Pago de beneficios a los accionistas
Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de LFMD para determinar si sus pagos de dividendos están cubiertos por los beneficios.
Pago en efectivo a los accionistas
Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que LFMD no ha comunicado ningún pago.
Descubre empresas que pagan buenos dividendos
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/06/11 19:38 |
| Precio de las acciones al final del día | 2026/06/11 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
LifeMD, Inc. está cubierta por 10 analistas. 8 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Anderson Schock | B. Riley Securities, Inc. |
| David Larsen | BTIG |
| Sarah James | Cantor Fitzgerald & Co. |